Biodesix (NASDAQ:BDSX) Director Acquires $328,937.00 in Stock

Biodesix, Inc. (NASDAQ:BDSX) Director Jack Schuler bought 13,700 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was bought at an average cost of $24.01 per share, for a total transaction of $328,937.00. Following the transaction, the director directly owned 540,810 shares of the company’s stock, valued at $12,984,848.10. The trade was a 2.60% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Biodesix Trading Down 0.4%

BDSX stock traded down $0.09 during mid-day trading on Wednesday, hitting $24.22. 90,916 shares of the company were exchanged, compared to its average volume of 630,207. The company has a quick ratio of 2.85, a current ratio of 2.85 and a debt-to-equity ratio of 5.12. The firm has a market capitalization of $255.55 million, a P/E ratio of -7.64 and a beta of 0.56. The business has a fifty day simple moving average of $20.02 and a 200-day simple moving average of $15.96. Biodesix, Inc. has a 12-month low of $5.26 and a 12-month high of $25.52.

Biodesix (NASDAQ:BDSX) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.19. Biodesix had a negative net margin of 26.97% and a negative return on equity of 788.19%. The business had revenue of $26.86 million for the quarter, compared to the consensus estimate of $26.03 million. On average, equities research analysts predict that Biodesix, Inc. will post -2.68 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Biodesix

Several institutional investors have recently modified their holdings of the business. Allworth Financial LP purchased a new stake in shares of Biodesix during the second quarter worth $112,000. BlackRock Inc. purchased a new position in Biodesix in the second quarter valued at $970,000. AIGH Capital Management LLC purchased a new position in Biodesix in the second quarter valued at $15,296,000. GSA Capital Partners LLP acquired a new position in Biodesix during the 2nd quarter worth $1,060,000. Finally, Walleye Capital LLC acquired a new position in Biodesix during the 2nd quarter worth $1,679,000. Institutional investors and hedge funds own 20.96% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on BDSX shares. Roth Capital assumed coverage on Biodesix in a research report on Wednesday, June 24th. They issued a “buy” rating and a $32.00 target price on the stock. Weiss Ratings upgraded Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 12th. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price objective (up from $26.00) on shares of Biodesix in a research note on Thursday, August 6th. Finally, Canaccord Genuity Group lifted their price objective on Biodesix from $27.00 to $35.00 and gave the company a “buy” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Biodesix currently has a consensus rating of “Moderate Buy” and an average price target of $31.33.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.